176 related articles for article (PubMed ID: 24013127)
1. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
van Erp NP; de Wit D; Guchelaar HJ; Gelderblom H; Hessing TJ; Hartigh Jd
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():33-43. PubMed ID: 24013127
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
[TBL] [Abstract][Full Text] [Related]
3. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
4. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
5. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
6. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ
Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M
Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
9. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
[TBL] [Abstract][Full Text] [Related]
10. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Götze L; Hegele A; Metzelder SK; Renz H; Nockher WA
Clin Chim Acta; 2012 Jan; 413(1-2):143-9. PubMed ID: 21945732
[TBL] [Abstract][Full Text] [Related]
11. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
Honeywell R; Yarzadah K; Giovannetti E; Losekoot N; Smit EF; Walraven M; Lind JS; Tibaldi C; Verheul HM; Peters GJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1059-68. PubMed ID: 20382575
[TBL] [Abstract][Full Text] [Related]
12. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies.
He Y; Zhou L; Gao S; Yin T; Tu Y; Rayford R; Wang X; Hu M
J Pharm Biomed Anal; 2018 Jan; 148():65-72. PubMed ID: 28965046
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
Pang YY; Tan YL; Ho HK
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
[TBL] [Abstract][Full Text] [Related]
15. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.
Kiesel BF; Parise RA; Wong A; Keyvanjah K; Jacobs S; Beumer JH
J Pharm Biomed Anal; 2017 Feb; 134():130-136. PubMed ID: 27907855
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Teunissen SF; Jager NG; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1677-85. PubMed ID: 21543272
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
